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C5
ECONOMIC ASPECTS OF
ACUTE LIMB ISCHAEMIA
Compared with the management of critical limb
ischaemia, the investigations and treatments of ALI
have been subjected to very few economic analyses,
possibly because of the urgency and the limited
number of therapeutic options. The economic data
on amputation is presented in Economic Aspects of
Critical Limb Ischaemia, D 5, P 5232.
The health care costs of treating an occlusion in an
isolated native peripheral artery were estimated by
Janosik et all and Ourielet al,2 from several retro-
spective series of patients treated with either throm-
bolytic therapy, with urokinase or streptokinase, or
surgical thrombectomy. Only the costs of the initial
admission were included, and hospital charges were
used as a proxy for costs. Comorbid conditions were
not documented. The most striking results are the
convergence of economic data calculated between
1990 and 1993 that show similar mean charges.
These range from $20,000 (EUR 18,600) to $26,000
(EUR 24,180) for all three treatments. Patients treat-
ed with urokinase have shorter length of stay but
higher drug charges. However, the relevance of the
comparison is limited by the fact that these were ret-
rospective studies. Thus, it appears that when con-
sidering different strategies for thrombectomy, cost
is not a decision criterion.' A similar figure of
$25,000 (EUR 23,250) for thromboembolectomy was
found by Hoch et al 4 in 1994, who reported higher
costs of $45,000 (EUR 41,850) and worse results
when urokinase was used as well in the procedure.
Lower costs of surgical revascularisation were found
by Singh et al in a 1993 to 1995 study in the United
Kingdom. Their $6,617 (EUR 6,154) cost per patient
included the cost of the initial procedure and a 12-
month follow-up," This study did not compare sur-
gery with other treatments.
Thus, the choice between surgery and thromboly-
sis for ALI should not be based on economic factors
but rather on predicted best clinical outcome. This is
because both treatments have similar hospital costs
in one study, whereas surgery is the better option in
terms of results and lower costs from another study.
(See Results of Surgical and Endovascular
Procedures for Acute Limb Ischaemia, C 4.4, P 5132,
for analysis of the conflicting data comparing
catheter-directed thrombolysis and surgery for
ALI.)
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Critical Issue 26: Economic data on acute limb
ischaemia
There is a need for prospective studies document-
ing the costs of treating patients with acute limb
ischaemia. To add significant data to this field,
future studies should
• Define the duration and severity of ischaemia
• Specify the aetiology (thrombus/embolus)
• Prospectively compare, with randomisation, the
therapeutic options
• Document the use of resources (see
Recommendation 7)
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C6
CLINICAL TRIAL ISSUES IN ACUTE LIMB
ISCHAEMIA
The appropriate treatment of acute limb ischaemia is
difficult to extract from the literature. This is because
of individual or institutional reports of the results of
both surgical and thrombolytic treatment either con-
taining bias or not comparing with concurrent con-
trols or not using standardised reporting practices. It
is also because several recent trials comparing these
two modalities have, in retrospect, been seen to have
serious flaws. Conversely, now that these are appar-
ent, guidelines for future trials can be developed
that should further clarify the proper selection of
patients for treatment and the treatment of choice in
specific settings. The following are some of the criti-
cal issues in designing a trial in ALI, with examples
of the problems that have been encountered in the
past.
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C 6.1.1
Entry Criteria
The issue of entry criteria includes selection of
patients for study by severity and duration of
ischaemia, using appropriate inclusion/exclusion cri-
teria, etc. The primary goal of treatment of ALI is limb
salvage. This and patient survival should be the main
focus of most studies (see later discussion of end
points). However, many studies have included not
only all patients with acute thrombosis but even those
with subacute and chronic thromboses, that is, includ-
ing patients regardless of the severity of ischaemia
and the need for or urgency of treatment.
For example, almost three quarters of the patients
entered into the STILEtrial had occlusions of more than
14 days' duration! Few of those under 14 days had class
II acute limb-threatening ischaemia. One problem with
such trials is that where a protocol is complex, with con-
siderable time needed to fully inform, register, and ran-
domise the patient, it is difficult and bordering on
unethical to include those needing immediate revascu-
larisation. This may be why a simpler single institu-
tional trial such as the Rochester trial was the only one
able to enter class II patients exclusively-
C 6.1.2
Intentlon-to-Treat Rule and Inclusion of Technical
Failures
These basic prerequisites for a proper trial have often
been neglected in the past, particularly in retrospective,
personal, or institutional series. It is impossible to be
sure in the latter reports how many cases of technical
failures, for example, failure to gain access for COT ther-
apy, have been eliminated. It may have been a more
prevalent practice than suspected. After many encour-
aging reports of personal or institutional series claiming
75% to 85% success for COT, it was a rude awakening
when most of the prospective randornised trials encoun-
tered a failure-to-gain-access rate of close to 25%, from
presumably well-selected participating centres.
Undoubtedly, similar practices occur in reporting surgi-
cal experiences, but this highlighted an aspect of throm-
bolytic therapy that had not been fully appreciated,
Recommendation 66: Intention-to-treat analysis
and technical failures in trials in acute limb
ischaemia
• The intention-to-treat rule should be observed.
• Primary treatment failures (before treatment
using another modality and including technical
failures) should be reported separately, with a cat-
egorical breakdown as to cause.
C 6.1.3
Stratification of Treatment Groups and Post Hoc
Analysis
The word stratify may be used in two senses: to pro-
duce groups equivalent in risk factors for controlled
comparison of therapies or to separate groups by
risk factors to test their respective impact on thera-
peutic outcome. The latter meaning is used here.
Because prospective randomised trials tend to be
quite expensive, there is a tendency to avoid strati-
fying patients (ie, separating them into several treat-
ment groups by cert ain characteristics) to try to
achieve statistical positive results with the minimum
number of subjects. This is clearly a "double-edged
sword." Power projections to determine the number
of patients needed for statistical significance depend
on a predictable event rate (see C 6.1.7, Selection of
End Points, p S142) plus a good estimate of the
expected difference in end-point outcome between
treatment or control groups. Combining this with a
hope for the widest popular application of the new
treatment often results in negative trials of a treat-
ment that in truth is beneficial in certain selected
patients, something that only thoughtful stratifica-
tion could prove.
There is no better example of this than the STILE
trial (Surgery Versus Thrombolysis for Ischaemia of
the Lower Extremity). Because of failure to stratify
patients and the use of a composite end point, the
trialists were forced to use post !IOC anahjsis of sub-
groups, which were not prospectively identified, to
try to show some benefit for CDT.I In retrospect, the
trialists should have separated:
• those with truly limb-threatening ischaemia from
those without
• those with very recent occlusions from those pre-
senting after long delays
• those with native artery occlusions from those with
graft occlusions, and those with occluded vein
grafts from those with occluded prosthetic grafts
• those with proximal (aortoiliac) from those with
distal (infrainguinal) occlusive lesions
In some group comparisons, trends did not reach
statistical significance, and in others statistical sig-
nificance was achieved but discounted because def-
inition of the group was "post-hoc." It is becoming
increasingly evident that the di stinction between
a thrombotic and an embolic occlusion often cannot
be made before surgical exploration; therefore,
pretreatment stratification on this basis is
unreliable.
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Recommendation 67: Patient stratification in clini-
cal trials in acute limb ischaemia
• Different levels of ischaemia should either not be
combined in a study or should be stratified
beforehand.
• In addition to stratifying for the severity or dura-
tion of ischaemia, the following should be stud-
ied either separately or together by using stratifi-
cation as appropriate:
-native arteries and grafts
-vein and prosthetic grafts
C 6.1.4
Need for Standardised Reporting Practices
This applies to many aspects of the reported literature
in this area, but the failure to identify the level of
ischaemia of the patients treated and either select one
level (II) or stratify for the levels, has caused the most
problems. Previous examples have been given from
the prospective randomised trials, but there are equiv-
alent examples from retrospective, noncontrolled
studies. For example, one study, which claimed 85%
successful lysis with an 8.3% amputation rate and
1.6% mortality for all levels of ischaemia, achieved
patient and limb survival in 62.5% of class III level
"irreversible ischaemia." The 100% success rate in
class I and an 84% success rate with lysis alone in class
II, associated with no deaths and only an 8% amputa-
tion rate, were equally remarkable, until it was seen
that an ankle pressure of greater or less than 30 mm
Hg. was a primary criterion for separating these two
groups, indicating that most of these cases did not
have truly acute limb-threatening ischaemia.
Recommendation 68: Standardised reporting prac-
tices in acute limb ischaemia
• Standard classification should be used for levels
of ischaemia.
• Standardised reporting practices should be used.
• Duration of ischaemia should be reported as the
basis for further stratification.
• Anatomic characteristics of underlying lesion
should be reported.
C 6.1.5
Combining Treatments Within Groups
One of the major problems with trials of thrombolysis
versus surgery for ALI is that comparisons are not only
made between thrombolysis versus thrombectomy for
Eur J Vase Endovasc Surg Vol 19 Supplement A, June 2000
clot removal but include a comparison of PTA versus
surgery for the treatment of the underlying lesion.
These treatments are commonly linked in practice, so
that thrombolysis is likely to be followed by PTA, and
bypass is likely to follow thrombectomy even if the
underlying lesion is an arteriosclerotic narrowing.
There may even be an inherent bias in the choice of
treatment of the underlying lesion. For example, in the
Rochester trial, performed by surgeons, most of the
underlying lesions were treated by surgery rather than
PTA, which is quite the opposite of other trials. Though
admittedly difficult to control and dissociate, the effects
of these separate components of therapy must be inde-
pendently assessed by the use of secondary end points,
including a primary failure rate for initial therapy.
C 6.1.6
Control of Treatment Crossovers
This includes allowing for treatment crossovers in
comparing treatment efficacy. In trials comparing sur-
gery versus thrombolysis, because of the severity of
the ischaemia, and possibly even immediate limb
threat, thrombolysis failures are treated by surgery,
with successful outcome credited to thrombolysis,
whereas surgical failures are not treated by thrombol-
ysis and remain failures. This apparent inequity is dis-
missed by some by pointing out that the goal of avoid-
ing surgical risk is a valid one. However, in most of the
trials, the crossover to surgery is high; for example, in
the Rochester study? it was over 60%. Comparing pri-
mary therapeutic failures as an additional end point
would counteract the misimpression left by a high rate
of unidirectional treatment crossover.
Recommendation 69: Combining treatments within
study groups
• The efficacy of the method of clot removal and the
method of treating the underlying lesion should
be separated as much as possible. They may be
independently assessed by the use of secondary
end points, including a primary failure rate for
ini-tial therapy.
• Subsequent treatment by the alternative modality
(crossover) should not be arbitrary but strictly
controlled by protocol and their rates reported.
C 6.1.7
Selection of End Points
The selection of appropriate end points takes skill
and foresight. The goals of therapy are patient and
limb survival, and these should be the primary end
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points. Two end points may be appropriately com-
bined if measured at the same time. However, in the
Rochester trial, the statistically significant mortality
advantage to thrombolysis might have been lost if
combined with limb loss, because surgery and throm-
bolysis both had an 85% limb salvage rate at 1 year
(albeit due to surgery in over 60% of the thrombolysis
cases). Combining more than two end points to
achieve statistical significance may be equally unde-
sirable, particularly if they carry unequal weight. In
the STILE trial, combining mortality, limb loss, major
complications, and persisting or recurrent ischaemia
into one combined clinical outcome end point
achieved such statistical power that the trial was
stopped by the safety control committee before suffi-
cient data could be accumulated to allow statistically
significant subgroup analysis.'
Based on experience in previous trials in which
there had been difficulty showing an advantage for
thrombolysis and a high rate of crossover to surgery
had been observed, TaPAS trialists believed that even
if the two treatments were not significantly different in
the accepted end points of patient survival and limb
salvage, thrombolysis could be shown to hold an
advantage if it reduced the scope of the surgery per-
formed.' In fact, a major claim of the TaPAS trial was
equivalence in survival and limb salvage but reduced
surgical risk. Unfortunately, the treatment severity
scale used was somewhat flawed. For example, a dig-
ital amputation was considered a greater procedure
than a bypass, and a direct bypass was considered a
greater procedure than a thromboembolectomy with
local revision (eg, endarterectomy or patch angioplas-
ty). Neither of these is true in terms of morbidity risk.
Morbidity and success in relieving ischaemia are valid
secondary end points, but these were pointedly left
out of the TaPAS study after the experience of the
STILE trial.
Recommendation 70: End points in trials in acute
limb ischaemia
• Primary end points: Mortality and limb salvage
are primary end points, the latter only in class II
level cases in which there is true limb threat. They
may be combined.
• Secondary end points: Major morbidity and per-
sisting/recurrent ischaemia are appropriate sec-
ondary end points, as is primary treatment failure.
Reduction in the scope or severity of ischaemia
are better assessed by standard morbidity assess-
ments, including length of stay in an intensive
care setting and in the hospital.
C 6.1.8
Adequate Follow-up
Thirty day or even 6-month outcomes may be insuffi-
cient, particularly if one treatment has a shorter dura-
bility of success than the other. In the STILE trial, the
initial report used these early end points, but, consid-
ering the high rate of persistent or recurrent ischaemia
in the thrombolysis group, longer follow-up would be
more appropriate. Short follow-up not only may con-
found life-table projections, but it does not allow the
impact of re-treatment and its effect on mortality, mor-
bidity, limb loss, and costs to be properly included in
the assessment.
Recommendation 71: Duration of follow-up for
trials in acute limb ischaemia
Follow-up should be at least 6 months for mean-
ingful comparisons of therapy.
C 6.1.9
Inclusion of Cost-effectiveness Analysis
Cost-effectiveness analysis is important, more so if the
treatments end up being otherwise equivalent. Rough
cost analyses were done in two of the trials, showing
no advantage to thrombolysis, possibly because of the
frequent need to cross over to surgery. Formal analysis
of actual total costs, carried out at least to 1 year, are
needed.
Recommendation 72: Cost-effectiveness analysis in
trials in acute limb ischaemia
Cost-effectiveness analysis should be included in
trials comparing different treatments of acute limb
ischaemia.
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